Dermavant's Vtama works again in eczema as Roivant subsidiary seeks label expansion next year
Almost a year to the day after Dermavant Sciences landed its first FDA approval for plaque psoriasis for Vtama, the drugmaker is out with its second successful Phase III trial of the topical cream for treating eczema.
The Roivant subsidiary said the steroid-free, vanishing cream worked again in a late-stage study identical to the first, which read out in March. With data from a little more than 800 patients across the two studies, dubbed ADORING 1 and 2, the company plans to ask the FDA for a label expansion in atopic dermatitis for adults and kids as young as age 2 in the first quarter of 2024.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.